iRhythm Technologies, Inc. Profile Avatar - Palmy Investing

iRhythm Technologies, Inc.

iRhythm Technologies, Inc., a digital healthcare company, provides ambulatory electrocardiogram (ECG) monitoring products for patients at risk for arrhythmias in the United States. It offers Zio service, an ambulatory cardiac monitoring solution that com…

Medical - Devices
US, San Francisco [HQ]
Financials

Analysts

Earnings
Reported
Past Estimate Consensus
Future Estimate Consensus
EPS Revenue EBITDA EBIT SGA
FY EPS Revenue [mil.] Profit [mil.] EBITDA [mil.] EBIT [mil.] Expenses · SGA [mil.]
E E E E E E
All monetary values are presented in USD ($). E stands for Estimate.
2016 - -1.448 - 62 - -44 - -13 - -17 - 50
2017 -3.9500 -1.167 64 97 -20 -26 -17 -21 -15 -24 51 79
2018 -1.3000 -1.863 98 144 -29 -35 -26 -31 -27 -32 84 99
2019 -2.0200 -2.031 147 213 -48 -49 -42 -43 -43 -49 131 168
2020 -2.1600 -1.532 214 263 -54 -49 -52 -37 -54 -49 179 234
2021 -1.5800 -3.525 265 319 -43 -112 -42 -98 -43 -110 197 311
2022 -3.4600 -3.462 322 408 -101 -161 -99 -125 -99 -157 274 365
2023 -3.8800 -3.102 410 490 -116 -123 -85 -137 -87 -173 322 402
2024 -4.0400 -3.748 492 584 -123 -114 -91 -129 -114 -158 385 467
2025 - -1.996 - 679 - -58 - -150 - -184 - 543
2026 - -0.909 - 796 - 2.F10X/td> - 2.F101/td> - 2.F101 - 2.F101
2027 - 0.730 - 984 - 1.F11X/td> - 1.F111/td> - 1.F111 - 1.F111
2028 - 1.500 - 1,167 - 0.F12X/td> - 0.F121/td> - 0.F121 - 0.F121
Institutional Sentiment
Morgan Stanley
1Y Ago:
Overweight
Prev. Grade
Overweight
Nov. 6, 2024
Overweight
JP Morgan Chase
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Citigroup
1Y Ago:
n/a
Prev. Grade
n/a
Latest
n/a
Overall Consensus
Grading Consensus
Click to each, to see the grade
Price Target Consensus

-8.718% $7.88 · MISS

Nov. 6, 2024
Price Then
$86.68
Price Target
$98.27
Price Now
$90.39
End of IRTC's Analysis
CIK: 1388658 CUSIP: 450056106 ISIN: US4500561067 LEI: - UEI: -
Secondary Listings
IRTC has no secondary listings inside our databases.